Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1477 - Eribulin mesylate for HER2- metastatic breast cancer; analyses of pattern of disease progression and outcomes from the real world (106P)

Date

18 Nov 2017

Session

Poster lunch

Topics

Cytotoxic Therapy;  Breast Cancer

Presenters

Junichiro Watanabe

Citation

Annals of Oncology (2017) 28 (suppl_10): x26-x34. 10.1093/annonc/mdx654

Authors

J. Watanabe

Author affiliations

  • Breast Oncology, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
More

Resources

Abstract 1477

Background

The subanalysis of prospective randomized trials of E suggested E suppressed development of new lesion [NL] and it led to improvement of overall survival (Twelves, BCRT, 2015), however, behaviors of disease in real-world patients (pts) have not been well discussed.

Methods

Outcomes of HER2-MBC pts who received E at our institute from November 2011 to present were reviewed. Statistical analyses were performed using the chi-square test, the Kaplan-Meyer method.

Results

We identified total 128 (90 ER+, 38 ER-) HER2-MBC who received E at least 2 cycles in our institute. Median age at the initiation of E were as follows; overall, 58 (range 30-77); ER+, 60 (30-77); ER- 55.5 (32-71). Median number of regimens prior to E were as follows; overall, 1 (range 0-8); ER+, 1 (0-6); ER-, 2 (0-8). While all pts had a history of anthracycline and/or taxane in ER- subset, Number of involved organ were 2 (1-5) in overall and both subsets and no significant difference was seen in the pattern of visceral involvement. Most of (122/128, 95.5%) the pts was discontinued E therapy, and median time-to-treatment failure (TTF) were as follows; overall, 125.0 days (95% confidence interval [CI] 43.0-328.0); ER+, 134.0 days (95%CI 62.0-314.0); ER-, 104.0 (95%CI 42.0-230.0). Reasons for the discontinuation of E were as follows; progression of known lesion(s), 77 (63.1%); development of NL, 27 (22.1%), decrease of performance status, 11 (9.0%); intolerable toxicity, 6 (4.9%); other, 1 (0.9%). In ER- subset, development of NL was more frequently seen compared to ER+ subset, however, it was not statistically significant. (7/20 vs 10/67, P = 0.12, chi-square). Multivariate cox regression analyses disclosed some risk factors for TTF as follows; liver metastasis, hazard ratio [HR] 0.39, P 

Conclusions

Our single institutional review with some limitations disclosed eribulin monotherapy revealed equivalent effect shown in prospective studies.

Clinical trial identification

Legal entity responsible for the study

Junichiro Watanabe

Funding

None

Disclosure

J. Watanabe: Advisory board member of Eisai Co., Ltd. Honoraria from Eisai Co., Ltd.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.